TME Pharma N.V. announced that certain lenders have accepted to extend the maturity of their loan by a further 12 months. TME Pharma now has cash runway into second quarter 2027. An agreement reached with certain lenders who participated in the May and August 2025 fundraisings (including board members and CEO) lending the Company at such time a total amount of approximately EUR 2.06 million, representing 93.2% of the total May and August 2025 loans.
The maturity of these loan agreements has been extended by 12 months, and in consideration for the extension of the loan repayment, the term of the warrants has been extended until December 31, 2030. The lenders have received 30% extra warrants at the same strike price as the current warrants (EUR 0.10 and EUR 0.11 respectively for the May and August 2025 loans). These extra warrants are subject to a lock-up until January 1, 2029, unless the share price is EUR 0.25 or higher.
In case of full exercise of all the new warrants under the amended loan agreements, the Company could receive a total additional amount of approximately EUR 678,000 in exchange for the issuance of 6,584,116 shares (which is approximately 7% dilution). TME Pharma will redeem bonds early on March 11 to bondholders who did not wish to extend. The amount is EUR 163,562.50 including interest.
